Literature DB >> 16055578

Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating.

David M Haas1, Coy A Flowers, Christine L Congdon.   

Abstract

OBJECTIVE: To estimate rubella, rubeola, and mumps (MMR) susceptibilities in pregnant women and determine the percentage not immune to rubeola or mumps, depending on rubella immunity status. A secondary objective was to assess costs of vaccination and testing programs aimed at eliminating these viral susceptibilities to determine an optimal strategy.
METHODS: This was an observational study of women presenting for prenatal care. All women had MMR antibody titers measured. Viral susceptibilities were compared by age, gravidity, parity, and recall of vaccine booster. A logistic regression was performed to assess for predictors of MMR immunity. A cost comparison of different screening and vaccination strategies was performed.
RESULTS: Overall, 91 (9.4%) women were susceptible to rubella, 161 (16.5%) to rubeola, and 159 (16.3%) to mumps. Three hundred seventeen (32.6%) were susceptible to at least 1 virus, whereas only 17 (1.7%) were susceptible to all 3. Of the women who were immune to rubella, a large percentage were not immune to either rubeola or mumps (n = 226, 25.6%). Only 74.2% of women who knew they had a booster vaccine were immune to all components of the MMR vaccine. Receiving a booster was predictive of immunity to all 3 viruses. A cost analysis demonstrated that broader screening strategies are more comprehensive and more expensive.
CONCLUSION: The current screening and vaccine program has left many reproductive-aged women susceptible to rubella, rubeola, and mumps infections. Perhaps a more comprehensive viral screening program is needed to ensure immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055578     DOI: 10.1097/01.AOG.0000171110.49973.e3

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.

Authors:  P Plans; F de Ory; M Campins; E Álvarez; T Payà; E Guisasola; C Compte; K Vellbé; C Sánchez; M J Lozano; I Aran; A Bonmatí; R Carreras; M Jané; L Cabero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 3.267

Review 2.  What Obstetric Health Care Providers Need to Know About Measles and Pregnancy.

Authors:  Sonja A Rasmussen; Denise J Jamieson
Journal:  Obstet Gynecol       Date:  2015-07       Impact factor: 7.661

3.  Congenital rubella syndrome after rubella vaccination in 1-4 weeks periconceptional period.

Authors:  R Nasiri; J Yoseffi; M Khajedaloe; M Sarafraz Yazdi; F Delgoshaei
Journal:  Indian J Pediatr       Date:  2009-04-06       Impact factor: 1.967

Review 4.  Health economics of rubella: a systematic review to assess the value of rubella vaccination.

Authors:  Joseph B Babigumira; Ian Morgan; Ann Levin
Journal:  BMC Public Health       Date:  2013-04-29       Impact factor: 3.295

5.  Presumed cases of mumps in pregnancy: clinical and infection control implications.

Authors:  Svjetlana Lozo; Ahmed Ahmed; Edward Chapnick; Mary O'Keefe; Howard Minkoff
Journal:  Infect Dis Obstet Gynecol       Date:  2012-02-12

6.  Rubella Immunity among Pregnant Women in Jeddah, Western Region of Saudi Arabia.

Authors:  Sharifa A Alsibiani
Journal:  Obstet Gynecol Int       Date:  2014-06-19

7.  Does rubella immunity predict measles immunity? A serosurvey of pregnant women.

Authors:  Colleen M Kennedy; Barbara A Burns; Kevin A Ault
Journal:  Infect Dis Obstet Gynecol       Date:  2006

8.  Evaluation of rubella immunity in a community prenatal clinic.

Authors:  Edward C Nwanegbo; Thor Swanson; Oluseyi Vanderpuye; Carlos F Rios-Bedoya
Journal:  ISRN Family Med       Date:  2013-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.